Search Results 271-280 of 18882 for alzheimers
Verubecestat is a BACE inhibitor because it cuts a large protein called the Alzheimer precursor protein into pieces that include one fragment called beta- ...
That number is expected to triple by 2050 if effective treatments cannot be found. Alzheimer's has no cure and the five medications the U.S. Food and Drug ...
Watch Mayo Clinic neurologist Ronald C. Petersen, M.D., Ph.D., talk about mild cognitive impairment on HBO — The Alzheimer's Project. Research Profiles. Edit ...
Last week, the Food and Drug Administration approved aducanumab to treat Alzheimer's disease, which is a progressive brain disorder that is the most common ...
An estimated 5.5 million Americans are struggling with Alzheimer's disease and recent reports claim cases of Alzheimer's will triple by 2050. Patients, ...
Researchers study risk factors, predictors, diagnostic techniques, and potential treatments for Alzheimer's disease and other conditions. Read more about the ...
... Alzheimer's Disease (AD) and predict disease progression. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease ...
Sleep Characteristics, Cognitive Function, Alzheimer's Disease and Vascular Pathology Biomarkers in Cognitively Unimpaired Older Adults · Overview · Participation ...
U.S. Senator Susan Collins, the Chairman of the Senate Aging Committee and Co-Chair of the Congressional Task Force on Alzheimer's Disease, and Senator Claire ...
A Third Protein Provides Clue. Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer's ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.